Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | How It Works Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationType 2 DiabetesGLP-1 Series Issue 5GLP-1

ADA: Efficacy and Safety of Lixisenatide Once-Daily vs. Exenatide Twice-Daily in Type 2 DM Inadequately Controlled on Metformin (GetGoal-X)

This randomized, open-label, parallel-group, multicenter, 24-wk main treatment study, followed by a variable extension of at least 52 wk, compared the efficacy and safety of lixisenatide 20 µg QD and exenatide 10 µg BID in 634 T2DM patients insufficiently controlled on metformin ≥1.5 g/day (mean age 57.4 yr, diabetes duration 6.8 yr, BMI 33.6 kg/m2, HbA1c 8.0%) [NCT00707031]....
Advertisement

Stepwise dose increases were used in both groups to a maximum 20 µg/day. The primary objective was to demonstrate non-inferiority of lixisenatide vs. exenatide for HbA1c reduction at Wk 24 (predefined non-inferiority margin 0.4%). Hereafter, the 24-wk main treatment period data are presented.

Lixisenatide QD achieved its primary endpoint of non-inferiority in HbA1c reduction vs. exenatide BID (Table). Improvements in mean FPG and the % patients achieving HbA1c <7.0% were comparable between groups (Table). Mean body weight significantly decreased from baseline: 94.5 to 91.7 kg with lixisenatide and 96.7 to 92.9 kg with exenatide. The proportion of patients with AEs and serious AEs was generally comparable between the lixisenatide and exenatide groups. Discontinuations due to AEs (mainly GI events) were 33 (10.4%) lixisenatide and 41 (13.0%) exenatide. Significantly fewer patients experienced symptomatic hypoglycemia with lixisenatide, with 6-fold fewer hypoglycemic events (Table). No severe episodes were reported.

Overall GI tolerability appeared better for lixisenatide vs exenatide, with fewer cases of nausea and vomiting (Table). More lixisenatide patients tolerated the target dose of 20 µg/day (93% vs.83% exenatide). In conclusion, as add-on to metformin, lixisenatide QD was non-inferior to exenatide BID at improving HbA1c, but with less hypoglycemia, slightly less weight loss and better GI tolerability at Wk 24.[figure1]

GLP1-5-HIW2

Authors: JULIO ROSENSTOCK, DENIS RACCAH, LASZLO KORANYI, LAURA MAFFEI, GABOR BOKA, PATRICK MIOSSEC, JOHN E. GERICH- ADA Scientific Sessions Late Breaking Abstract Sunday, June 26, 2011 Abstract -33LB

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 July, 2011 and appeared in  MedicationType 2 DiabetesGLP-1 Series Issue 5GLP-1

Past five issues: Diabetes Clinical Mastery Series Issue 211 | Issue 751 | Humulin Insulin Special Edition October 2014 | Diabetes Clinical Mastery Series Issue 210 | Issue 750 |


Cast Your Vote
Do your teenage patients manage their diabetes well?
Search Articles On Diabetes In Control